Mutations in neurokinin B (NKB) and its receptor, NK3R, were identified in human patients with hypogonadotropic hypogonadism, a disorder characterized by lack of puberty and infertility. Further studies have suggested that NKB acts at the level of the hypothalamus to control GnRH neuron activity, either directly or indirectly. We recently reported that treatment with senktide, a NK3R agonist, induced GnRH secretion and expression of c-fos mRNA in GT1-7 cells. Here, we map the responsive region in the murine c-fos promoter to between Ϫ400 and Ϫ200 bp, identify the signal transducer and activator of transcription (STAT) (Ϫ345) and serum response element (Ϫ310) sites as required for induction, a modulatory role for the Ets site (Ϫ318), and show that induction is protein kinase C dependent. Using gel shift and Gal4 assays, we further show that phosphorylation of Elk-1 leads to binding to DNA in complex with serum response factor at serum response element and Ets sites within the c-fos promoter. Thus, we determine molecular mechanisms involved in NKB regulation of c-fos induction, which may play a role in modulation of GnRH neuron activation. (Endocrinology 155: 3909 -3919, 2014) 
R
eproductive function and pubertal development is controlled by the pulsatile release of GnRH. Human genetic studies revealed that neurokinin B (NKB) signaling is necessary for normal reproductive maturation and function, including the initiation of puberty and maintenance of pulsatile GnRH (1, 2) . Disruption of NKB/neurokinin 3 receptor (NK3R) signaling due to mutation of either NKB or NK3R leads to gonadotropin deficiency and results in idiopathic hypogonadal hypogonadism (3, 4) . Because pulsatile GnRH treatment of patients with NKB or NK3R mutations rescues serum gonadotropin levels, NKB likely functions at the level of the hypothalamus to regulate the release of GnRH (3) . NKB is coexpressed with kisspeptin and dynorphin in kisspeptin-neurokininBdynorphin (KNDy) neurons in the arcuate nucleus in the hypothalamus (5-7). In addition, KNDy neurons express NK3R and respond to intracerebroventricular injection of senktide with induction of c-fos, a marker of neuronal activation, in female rats (8) . Thus, it has been proposed that NKB acts in an autocrine and/or paracrine manner on KNDy neurons to induce the release of kisspeptin from KNDy neurons and indirectly stimulate secretion from GnRH neurons (9) . In addition, a subset of GnRH neurons has been shown to express NK3R, indicating that NKB may also directly regulate GnRH neurons (10, 11) . Recently, we showed that acute senktide treatment induced GnRH secretion in GT1-7 cells (12) . More recently, the direct regulation of GnRH neurons by NKB, independent of kisspeptin, was confirmed in vivo (13) . These data support a model whereby NKB can act directly to induce GnRH secretion from a subset of NK3R-expressing GnRH neurons.
We previously showed that senktide treatment induced c-fos mRNA by 1.7-fold and GnRH secretion in NK3R-expressing GnRH neurons in vitro. This is in agreement with previous in vivo studies that have shown the induction of c-fos in GnRH neurons to be correlated with increased GnRH secretion (14) . In addition to GnRH neurons and KNDy neurons in the arcuate nucleus (8) , c-fos has also been shown to be induced by senktide in NK3R-expressing neurons that coexpress vasopressin and oxytocin in the paraventricular nucleus (15, 16) in rats. Thus, the induction of c-fos may represent a common and functionally important end point of NK3R signaling.
The signaling pathways activated downstream from NK3R are largely unknown. NK3R has been suggested to signal via the activation of protein kinase C (PKC) based on studies that employed the structurally similar tachykinin receptor, NK1R (17) . However, differences have been observed between NK1R and NK3R in cellular trafficking upon ligand stimulation due to differences between their C-terminal domains and association with ␤-arrestins (18, 19) . Previously, we showed that long-term treatment with senktide, a NK3R-specific agonist (20) , repressed GnRH transcription in GT1-7 cells by a mechanism involving PKC (12) . However, in a time-course experiment, we found that the repression of the GnRH promoter required at least 8 hours of senktide treatment, suggesting that the GnRH promoter may not be the direct target of NK3R signaling. Indeed, we showed that senktide treatment rapidly induced c-fos mRNA and that the repression of GnRH transcription occurred in response to enhanced c-Fos protein binding at a novel activator protein-1 (AP-1) half-site in the GnRH enhancer 1 (12) .
The c-fos promoter has been studied extensively, and the signaling pathways leading to changes in transcription factor binding at several sites resulting in induction of gene expression have been characterized (21, 22) . Here, we employ the acutely regulated, well-characterized, murine c-fos promoter to elucidate the cellular pathways that are activated downstream from NK3R in GnRH neurons. Given the established roles of NKB and NK3R in regulating GnRH and LH secretion, these cellular pathways are important for advancing our understanding of hypogonadism and disorders of puberty in human patients.
Materials and Methods

Cell culture and treatments
GT1-7 cells (23) were cultured in 1ϫ DMEM containing 4.5-g/L glucose, L-glutamine, and sodium pyruvate (10-013-CV, Corning Cellgro; Mediatech, Inc) supplemented with 10% fetal bovine serum (Gemini Bio-Products) in 5% CO 2 /95% O 2 at 37°C. Senktide (Tocris Bioscience) was dissolved in Dulbecco's PBS without calcium or magnesium (Mediatech, Inc) supplemented with 0.1% Fraction V BSA (Sigma). PKC inhibitor Go6983 and phorbol 12-myristate 13-acetate (TPA) (Tocris Bioscience) were dissolved in dimethylsulfoxide (DMSO) (Sigma). Aliquots of stock solutions were stored at Ϫ80°C until use. Compounds that were dissolved in DMSO were further diluted in DMSO as needed before a final dilution of 1:1000 in media (0.1% DMSO final).
DNA constructs
The rat NK3R expression plasmid (18) was kindly provided by Dr Nigel W. Bunnett (University of California, San Francisco). The murine c-fos promoter, truncation, and cis-mutations and serum response factor (SRF) multimer luciferase reporters were previously described (24) . For the signal transducer and activator of transcription (STAT) multimer reporter, 4 copies of the STAT-binding site from the murine c-fos promoter (taTTCccgtCAAtg) were directionally cloned upstream of a thymidine kinase (TK) promoter and luciferase gene using NheI and XhoI sites. Positive clones were identified by restriction enzyme digest and confirmed by sequencing. The Elk-1 Gal4 and upstream activator sequence (UAS) constructs were a gift from Peter Kushner and Rosalie Uht. The suppressor of cytokine signaling 3 (SOCS3) expression was a gift from Dr Lu-Hai Wang (Institute of Molecular and Genomic Medicine, National Health Research Institute, Taiwan) (25) . SRF 1-266 was a gift from Dr Belaguli (26) .
Luciferase assays
For transient transfections, approximately 24 hours before transfection, GT1-7 cells were seeded into 24-well plates at a density of 150 000 cells per well. Cells were transfected with plasmid DNA using FuGENE 6 Transfection reagent (Promega) according to the manufacturer's protocol with a 3:1 ratio of FuGENE to DNA. Approximately 24 hours after transfection, cells were switched to serum-free media (DMEM ϩ 0.1% BSA). Cells were treated with pharmacologic agents as indicated in the figure legends. Approximately 48 hours after transfection, cells were rinsed 1ϫ with PBS and lysed with 55-L 100nM KPO 4 with 0.2% Triton X-100. A total of 20 L of cell lysate were used to measure luciferase activity on a Veritas Microplate luminometer (Turner Biosystems) by injection with 100-L luciferase assay buffer (25mM Tris [pH 7.4], 15mM MgSO 4 , 10mM ATP, and 65M luciferin) into each well. A total of 20 L of cell lysate were used to measure ␤-galactosidase activity using the Tropix Galacto-light ␤-galactosidase assay (Applied Biosystems). For each well, relative light units (RLU) for luciferase was normalized to ␤-galactosidase to control for transfection efficiency. Transfections were performed in triplicate, and experiments were repeated at least 3 independent times.
Electrophoretic mobility shift assays
A total of 3.5 ϫ 10 6 GT1-7 cells were seeded into each 10-cm plate. After 48 hours, cells were switched to serum-free media (DMEM and 0.1% BSA), and after 21 hours, cells were treated with vehicle or 100nM TPA. Nuclear extracts were prepared as previously described (27) , and protein concentration was deter-mined by Bio-Rad Protein Assay (Bio-Rad). Oligonucleotide probe sequences are listed in Table 1 . Annealed double-stranded oligonucleotides (1 pmol/L) were end-labeled with T4 Polynucleotide Kinase (New England Biolabs) and [␥ 32 P]ATP (7000 Ci/mmol; MP Biomedicals) and then purified using Micro BioSpin 6 Chromatography Columns (Bio-Rad). Binding reactions contained 2-g nuclear protein and 100 000 counts per minute of labeled probe in 10mM HEPES (pH 7.9), 25mM KCl, 2.5mM MgCl 2 , 1% glycerol, 0.1% Nonidet P-40, 0.25mM EDTA, 0.25% BSA, 1mM dithiothreitol, and 0.0125-g/L poly dIdC. For cold competitor, 1000-fold molar excess unlabeled competitor probe was added to the reaction and incubated for 10 minutes on ice. For supershift experiments, 2 g of an antibody that recognizes SRF (G20) (sc-335; Santa Cruz Biotechnology, Inc), phospho-SRF (Ser103) (4261; Cell Signaling Technology), phospho-Elk-1 (Ser383) (ab32799; Abcam), or normal rabbit IgG (sc-2027; Santa Cruz Biotechnology, Inc) was added to the reaction and incubated for 20 minutes on ice before the addition of labeled probe. After addition of probe, samples were incubated for 10 minutes at room temperature before loading on a 5% nondenaturing polyacrylamide gel in 0.25ϫ Tris-borate EDTA buffer. Gels were run for 2.5 hours at 200 -250 V and then dried under vacuum and exposed to film with L-Plus intensifying screens (Fisher Biotech).
Gal4 binding assay
To determine whether DNA binding of Elk-1 is increased by activation of either PKC or NK3R, GT1-7 cells in 24-well plates were transfected with 100 ng/L of TK␤Gal, 300 ng/L of Elk-1 Gal4, 300 ng/L of UAS, and 300 ng/L of either pcDNA 3.1 as control or NK3R expression vector. The media were then changed to serum-free 24 hours after transfection. After being serum starved for 24 hours, the GT1-7 cells were then treated with 0.5 mL of control vehicle, 30nM senktide, or 100nM TPA. The vehicle was DMEM with 0.1% BSA and 0.1% DMSO. The cells were harvested and analyzed using luciferase assay after 3.5 hours of treatment.
Statistical analysis
Statistical analysis of data was performed using JMP version 8 (SAS Institute, Inc). Data analyzed either by Student's t test or two-way ANOVA followed by Tukey honestly significant difference (HSD), as indicated in figure legends. When necessary to achieve a normal distribution, data were transformed by the method of Box and Cox. A P value of less than 0.05 was the cut-off for significance.
Results
NKB activates transcription of the c-fos gene
Previously, we reported that treatment of GT1-7 cells for 1 hour with 30nM senktide increased c-fos mRNA by 1.7-fold (12) . Because the level of c-fos mRNA could have been induced by either enhanced RNA stability or gene transcription, we first tested the hypothesis that senktide treatment increases c-fos gene transcription. GT1-7 cells were transiently transfected with a murine Ϫ1000-bp c-fos promoter on a luciferase reporter and either the NK3R expression plasmid or pcDNA3.1 control. The inclusion of the NK3R expression plasmid is due to decreases in the endogenous levels of NK3R in GT1-7 cells with passage such that to have consistent levels of receptor, GT1-7 cells expressing only transfected receptor are used (12) . Treatment for 3.5 hours with 30nM senktide significantly increased the activity of the Ϫ1000-bp c-fos promoter luciferase reporter in cells transiently transfected with NK3R ( Figure 1A ). These data indicate that senktide treatment induces c-fos gene transcription by a mechanism that specifically requires NK3R.
Next, a time-course experiment was performed to determine the treatment time required to achieve the maximal induction of c-fos luciferase reporter activity. Three hours of 30nM senktide treatment significantly induced the activity of a Ϫ1000-bp c-fos promoter when compared with vehicle ( Figure 1B) . A maximal level of induction was observed at 4 hours, and induction was reduced after 5 and 8 hours of senktide treatment. Further experiments used a 3.5-hour treatment.
A dose-response experiment was performed to determine the dose of senktide required to obtain a maximal induction of the Ϫ1000-bp c-fos promoter luciferase reporter. Using 3.5 hours of senktide treatment with doses spanning 5 logs, the activity of a Ϫ1000-bp c-fos luciferase reporter was induced with an EC 50 value of 0.04 Ϯ 0.01nM ( Figure 1C ). Because the 30nM dose of senktide was sufficient to obtain a maximal level of induction of c-fos promoter activity, this concentration was used in the following experiments. Alternatively, when testing for blockade by pathway inhibitors or dominant-negative expression constructs, a lower dose of 0.4nM senktide was used to achieve a submaximal level of induction for the c-fos luciferase reporter.
Induction of murine c-fos promoter activity by senktide maps between ؊400 and ؊200 bp Transient transfection with truncations of a Ϫ1000-bp c-fos luciferase reporter was employed to map the regions involved in the induction of promoter activity by senktide. Senktide significantly increases the activity of the wildtype Ϫ1000-bp c-fos reporter by 1.52 Ϯ 0.07-fold. This induction is maintained when the Ϫ1000-bp murine c-fos promoter is truncated to Ϫ600 and Ϫ400 bp. However, when the c-fos promoter is truncated to Ϫ200 bp, induction is no longer observed ( Figure 2A) . Thus, the region that mediates repression by NK3R activation maps to between Ϫ200 and Ϫ400 bp upstream from the transcription start site in the murine c-fos promoter.
Senktide-mediated induction of c-fos requires the SRF-and STAT-binding sites
The region between Ϫ200 and Ϫ400 bp of the c-fos promoter is known to contain elements including STAT, Ets, SRF, and AP-1 sites ( Figure 2B ), which have been previously reported to play a role in induction of c-Fos (28) . Using cis-mutations introduced into the Ϫ1000-bp c-fos luciferase reporter, we examined the role of each of these elements in the induction by senktide. Mutations of the STAT, Ets, or SRF sites decreased basal transcription of c-fos, whereas mutation of the AP-1 site led to an increased reporter activity of c-fos promoter ( Figure 2C ). These data suggest that c-fos transcription is negatively regulated by AP-1 and positively regulated by STAT, Ets, and SRF transcription factors. Moreover, mutation of either the STAT-or SRF-binding site resulted in a loss of induction in response to treatment with senktide ( Figure  2C ). These data indicate that the STAT-and SRF-binding sites are required for the induction of c-fos by NK3R. In addition, the induction of c-fos was decreased by the mutation of the Ets site, indicating that this site may also play a role in the induction response to the activation of NK3R. The induction of c-fos promoter activity by senktide requires NK3R and is time and dose dependent. A, GT1-7 cells were transiently transfected with 100 ng TK ␤-galactosidase, 400 ng of a Ϫ1000-bp mouse c-fos luciferase reporter, and either 200 ng of a rat NK3R expression vector or pcDNA3.1 vector control. Cells were treated for 3.5 hours with media change, vehicle, or 30nM senktide. B, GT1-7 cells were transiently transfected with 100-ng TK ␤-galactosidase, 400-ng Ϫ1000-bp c-fos luciferase reporter, and 200 ng of NK3R and then treated with 30nM senktide for 2, 3, 4, 5, or 8 hours. In both A and B, luciferase RLU data were normalized using a ␤-galactosidase internal control and are represented as fold vs cells treated with media change Ϯ SEM (n ϭ 3-4); *, senktide treated is different from vehicletreated control by Student's t test (P Ͻ .05). C, GT1-7 cells were transiently transfected with 100-ng TK ␤-galactosidase, 400-ng rat NK3R, and 400 ng of a Ϫ1000-bp c-fos luciferase reporter and treated for 3.5 hours with vehicle or senktide at the indicated doses. Luciferase RLU data were normalized using a ␤-galactosidase internal control and are represented as fold vs cells treated with media change Ϯ SEM (n ϭ 4). A representative dose-response curve fitted by nonlinear regression using a 4-parameter logistic equation is shown. The mean EC 50 was 0.037 Ϯ 0.01nM.
ined by luciferase assay to test the sufficiency of these sites for senktide-mediated induction. The multimer of the STAT sites was not induced by senktide treatment ( Figure  2D ). Thus, although required for induction of c-fos by senktide, the STAT-binding element on its own is not sufficient for NK3R-mediated induction (although we were unable to confirm that this multimer could be activated by individual growth factors). These data suggest that additional promoter elements are required for the STAT-dependent activation of c-fos transcription in response to NK3R agonist. In contrast, the activity of the luciferase reporter containing 4 copies of the SRE upstream of the TK promoter was significantly induced by 1.7-fold in response to 30nM senktide ( Figure 2D) . Furthermore, the amount of induction observed with the SRE multimer and the full-length Ϫ1000-bp c-Fos reporter was similar. These data indicate that the SRF site is both necessary and sufficient for the induction by senktide treatment. However, because the response to senktide is lost upon mutation of the STAT site, the SRF site alone is not sufficient for induction within the context of the c-fos promoter ( Figure 2C ).
Blockade of SRF and STAT signaling decreases c-fos promoter activity induced by activation of NK3R
Overexpression of SOCS3 can be used to suppress the transcriptional activity of STAT proteins (25, 29) . Similarly, the expression of a dominant-negative truncated SRF composed of amino acids 1-266 can block SRF activity (26, 30) . First, we found that expression of SRF 1-266 was able to fully block the senktide-mediated induction of activity from the SRE multimer luciferase reporter (Supplemental Figure 1) . To further confirm the roles of SRF and STAT in the induction of the c-fos promoter activity in response to NK3R activation, we employed overexpression of SRF 1-266 and SOCS3 in combination with the Ϫ400 c-fos promoter luciferase reporter. We used the Ϫ400-bp c-fos promoter because the truncation analysis (Figure 2A ) revealed that the upstream region was not necessary for the response to senktide. In comparison with empty vector control, the basal activity of the Ϫ400 c-fos luciferase reporter was significantly decreased in cells transfected with either SRF 1-266 or SOCS3 ( 
NK3R agonist activates transcription by a PKC-dependent pathway
To test whether activation of SRF requires signaling by PKC, GT1-7 cells transfected with the SRE multimer luciferase reporter were treated with the broad spectrum PKC inhibitor (31) Go6983 ( Figure 4A ). Cells treated with DMSO control showed a 1.6-fold induction of the SRE multimer in response to 0.4nM senktide, whereas in contrast, senktide failed to induce SRE multimer luciferase activity in cells pretreated for 30 minutes with either 10M or 20M Go6983. Next, to examine whether NK3R induction of the c-fos promoter activity requires signaling through PKC, GT1-7 cells transfected with the Ϫ400-bp c-fos luciferase reporter were treated with DMSO or either 10M or 20M Go6983 ( Figure 4B ). In contrast to the SRE multimer, the basal activity of the Ϫ400-bp c-fos promoter was decreased by treatment with either 10M or 20M Go6983. Also, in comparison with the DMSO-treated cells, the level of induction of the Ϫ400-bp c-fos promoter luciferase reporter in response to senktide was decreased by pretreatment with 10M and completely blocked with 20M Go6983.
Activation of PKC leads to changes in SRF binding to the c-fos promoter
Next, to determine whether binding of SRF or phosphorylated SRF (pSRF) to the SRE site in the c-fos promoter is changed by the activation of PKC signaling, EMSA was used. Briefly, nuclear extracts were prepared after the treatment of GT1-7 cells with TPA, an activator of PKC signaling, for either 7.5, 15, 30, or 60 minutes. Extracts were incubated with a radiolabeled, doublestranded oligonucleotide probe that contained the SRE sequence from the murine c-fos promoter and then run on a polyacrylamide gel. A single complex was observed bound to the SRE probe, and the intensity of this complex did not appear to change in response to TPA treatment (Figure 5A, lanes 1-5) . Preincubation of nuclear extracts with an antibody against SRF induced the supershift of the entire complex ( Figure 5A, lanes 13-17) , indicating that SRF protein is present in the complex bound to the SRE site. Moreover, the amount of complex shifted by antibody against SRF did not appear to change in response to TPA treatment ( Figure 5A, lanes 13-17) . Because the c-fos promoter has been shown to be occupied by proteins regardless of activity and stimulation by growth factors (32, 33) , the transcriptional activity of the c-fos and c-jun promoters is thought to be regulated mainly by protein phosphorylation in response to activation of MAPK cascades (34) . To determine whether the phosphorylation status of SRF protein bound to the SRE changed in response to TPA, a supershift was performed with an antibody directed against pSRF ( Figure  5A, lanes 6 -10) . The supershift of pSRF was somewhat decreased by 7.5 minutes of treatment with TPA and remained decreased for 60 minutes ( Figure 5A, lanes 6 -10) . The amount of complex that was not shifted by antibody against pSRF, indicating non-pSRF (SRF), also decreased by 7.5 minutes and appeared to recover by 30 minutes ( Figure 5A , lanes 6 -10). Thus, the activation of PKC appears to decrease the amount of pSRF bound to the SRE site in the c-fos promoter.
The Ets transcription factor Elk-1 is activated in response to PKC and NK3R signaling
Phosphorylation of SRF can modulate protein-protein interactions with ternary complex factors (TCFs) that bind to Ets sites (35) . We observed that the cis-mutation of the Ets site at Ϫ318 bp, adjacent to the SRE site at Ϫ310 bp, in the c-fos promoter, resulted in decreased basal activity and a reduced induction response to senktide (Figure 2C ). To determine whether there are changes in the complexes bound to SRF and Ets sites in response to activation of PKC, EMSA was performed with a doublestranded oligonucleotide probe containing both the SRE and Ets sites from the c-fos promoter. We observed 3 separate bands, indicating the binding of multiple complexes ( Figure 5B, lanes 1-5) . Preincubation with IgG control did not induce supershifting of any of the complexes. However, preincubation with IgG control reduced the intensity of the lowest complex (C3), indicating that it is likely the result of nonspecific binding (lane 11). Competition assays with wild-type and mutant unlabeled probes were used to determine which of these complexes bound to the Ets or SRE sites. Preincubation with an unlabeled wild-type oligonucleotide probe was able to compete for complexes bound to labeled probe as evidenced by a reduced intensity in both bands ( Figure 5B, lane 12) . In contrast, preincubation with unlabeled probe with mutations to disrupt A, Gel shift electromobility assay is performed using preincubation of nuclear extracts from GT1-7 cells treated for times indicated with 100nM TPA, an activator of PKC, with a double-stranded oligonucleotide probe with the SRE-binding site from the c-fos promoter. The complex bound to the probe (lanes 1-5) was shown to contain both phosphorylated and nonphosphorylated forms of SRF protein by supershift (SS) assay using preincubation with antibodies specific for SRF (␣-SRF, lanes 13-17) and pSRF (␣-pSRF, lanes 6 -10). The complex was not supershifted by IgG control (lane 11) and was competed away by unlabeled probe (Self, lane 12). Film was exposed for 4 days with an intensifying screen at room temperature. B, Gel shift electromobility assay was performed using preincubation of nuclear extracts from GT1-7 cells treated for times indicated with 100nM TPA, an activator of PKC, with a double-stranded oligonucleotide probe with the SRE and the adjacent Ets-binding sites from the c-fos promoter (lanes 1-5). The supershift assay was performed with antibodies specific for either pSRF (lanes 6 -10) or phosphorylated Elk-1 (lanes 16 -20) and the IgG control (lane 11). Competition assay was performed using an oligonucleotide probe with wild-type (WT) Ets ϩ SRF sites (lane 12), mutation () in either Ets (lane 13) or SRF (lane 14), or mutation in both SRE and Ets sites (lane 15). Film was exposed overnight with an intensifying screen at Ϫ80°C. Figure 5B, lane 14) , indicating that the higher band was the result of binding to Ets. In contrast, competition with probe containing a mutated Ets but an intact SRE site reduced the intensity of both bands ( Figure 5B, lane 13) , indicating that the SRE site was required for the formation of both complexes and binding to both the SRE and Ets sites. These data are in agreement with a previous study that showed that an SRF/ SRF dimer binds to the SRE and a ternary complex of SRF/SRF/TCF binds to SRE ϩ Ets in the c-fos promoter by EMSA (36) . Next, we sought to confirm the identity of proteins in the complexes using supershift assays. Upon preincubation with an antibody against pSRF, both complexes were supershifted ( Figure 5B , lanes 6 -10), indicating the presence of pSRF in both complexes. The TCF family of proteins that binds to Ets includes Elk-1, Sap-1, and Sap-2/ Net and Elk-1 has been shown to be the predominant TCF protein bound to the c-fos gene promoter in complex with SRF (36) . The phosphorylation of Elk-1 in response to serum stimulation was shown to positively regulate the c-fos promoter (37, 38) . To determine whether there is increased phosphorylation of Elk-1 in the complex bound to the SRE ϩ Ets site in response to the activation of PKC, supershift assays were performed with antibody against phosphorylated Elk-1 (Ser383) ( Figure 5B, lanes 16 -20) . The amount of phosphorylated Elk-1 bound to the probe was increased in response to TPA treatment ( Figure 5B , lanes 16 -20) . These data indicate that the activation of PKC leads to increased phosphorylation of Elk-1 protein bound in complex with SRF to the SRE ϩ Ets site in the c-fos promoter (compare lane 16 with lanes [17] [18] [19] [20] . Thus, the activation of c-fos transcription in response to NK3R agonist may involve PKC-dependent activation of Elk-1.
To determine whether Elk-1 is activated in response to the NK3R activation, a Gal4 binding assay was employed. GT1-7 cells were transfected with NK3R or the pcDNA3.1 control vector, a Gal4-Elk-1 fusion protein, and a Gal4 UAS luciferase reporter. In comparison with cells treated with vehicle control, luciferase reporter activity was significantly increased in response to TPA treatment in cells transfected with either pcDNA3.1 or NK3R, indicating increased association of Elk-1 with DNA after activation of PKC ( Figure 6 ). In addition, only the GT1-7 cells that were transfected with NK3R showed increased luciferase reporter activity in response to senktide, indicating that activation of NK3R signaling also leads to the activation of Elk-1 transcription factor activity.
Discussion
To elucidate the pathways acting downstream from NK3R in GnRH neurons, we sought to capitalize on the wellunderstood mechanisms of c-fos promoter regulation by growth factors and kinases. Depending on the stimuli and cellular model, various signaling pathways have altered binding at different cis-elements in the c-fos promoter. For example, growth factor stimuli, such as colonystimulating factor 1 and platelet-derived growth factor, signal through the Janus kinase (JAK)-STAT pathway to activate transcription of c-fos gene using a STAT-binding site at Ϫ345 bp upstream from the transcription start site (39) . Alternatively, ERK activation through phosphorylation by MAPK-dependent kinases leads to c-fos induction by Elk-1 phosphorylation and enhanced binding to a SRE located at Ϫ310 bp (40) . Finally, c-fos transcription was also shown to be regulated by binding of AP-1 transcription factors, including autologous regulation by c-fos protein, at an AP-1 site at Ϫ295 bp (22) . In this study, we found that mutation of either the SRF or STAT, but not the AP-1-binding site, disrupted the induction of c-fos promoter activity by senktide. As a result, we further investigated the cellular pathways that have been shown to regulate c-fos promoter activity by modulating the activity of SRF and STAT transcription factors. The STAT-binding site (TTCCCGTCAA) at Ϫ345 bp has been reported to contribute to c-fos induction in response to TPA, EGF, and serum by signaling through the JAK-STAT pathway (28) . The Tyr at the C terminus of STAT is phosphorylated and activated by JAK, and this allows dimerization of STAT1 with STAT3. The STAT heterodimer complex then binds to the STAT site to induce c-fos gene expression (24, 41) . In this study, cis-mutation of the STAT site at Ϫ345 bp in the c-fos promoter prevented induction by senktide. Therefore, we hypothesized that the induction of c-Fos by senktide may involve the activation of a JAK-STAT pathway downstream of NK3R. However, senktide failed to induce activity of a STAT multimer, a luciferase reporter containing 4 copies of the STAT-binding site, although we were unable to confirm that this multimer could be activated. These data indicate that although the STAT site in the c-fos promoter is required, the responsiveness of the promoter likely involves additional sites within the Ϫ400-bp region to senktide. Evidence suggests that STAT, SRF, and TCF proteins all contribute to c-fos promoter activation by granulocytemacrophage colony-stimulating factor in murine fibroblasts (35) . Here, dominant-negative SRF (1-266) and SOCS3 reduced the response to senktide to a greater degree when coexpressed than when expressed individually, suggesting that both STAT and SRF contribute towards the induction. Recently, in vivo evidence emerged to support a role for the JAK-STAT pathway in GnRH neurons in puberty and fertility. Female GnRH neuron-specific Jak2 conditional knockout mice (Jak2GϪ/Ϫ) were shown to have reduced GnRH expression, GnRH secretion, and GnRH neuron activity, as assessed by the expression of cFos. In addition, female Jak2GϪ/Ϫ mice exhibited delayed puberty and impaired fertility (42) . Thus, the JAK-STAT pathway appears to be essential for normal reproductive development and fertility through the regulation of GnRH neuron activity. It is possible that this could be through its requirement for the induction of c-fos.
The SRF site located at Ϫ310 bp in the c-fos promoter contains a core sequence known as the CArG box (CCATATTAGG) (22, 24, 43) . SRF protein has been shown to occupy this site, independent of exposure to serum stimulus, and, rather than DNA binding, its ability to activate transcription is thought to be mainly regulated through phosphorylation and ternary complex formation with TCF family proteins that bind to the adjacent Ets site (44) . We find that senktide treatment induced the activity of a luciferase reporter containing 4 copies of the SRE site. These data indicate that the SRF site alone is sufficient for senktide-mediated induction. These data support a role for both SRF and Ets in the transcription of c-fos gene in response to senktide.
NK3R is a G protein-coupled receptor. NK3R is thought to be coupled to G q /G 11 (17, 45) , which, when activated, hydrolyzes phosphoinositide into inositol triphosphate and diacylglycerol and results in PKC activation. In dorsal root ganglia neurons, activation of NK3R was reported to stimulate PKC activity and inhibit N-type Ca 2ϩ channels (46) . Previously, we showed that senktide-mediated repression of GnRH transcription involved signaling by PKC (12) . Interestingly, like senktide, TPA, an activator of PKC, has been shown to induce c-fos transcription by activation of SRF (47) . Here, we show that TPA induces phosphorylation of Elk-1, a TCF family protein, and that Elk-1 binds to the Ets site, in a complex with SRF. Moreover, pretreatment with the PKC pathway inhibitor Go6983 blocks the response to senktide of the SRF multimer and the Ϫ400-bp c-fos promoter luciferase reporter. Thus, PKC signaling is required for the induction of c-fos transcription by NK3R, presumably through enhancing transcriptional activation by SRF.
In vivo studies have shown NK3R signaling to be essential for reproduction and the regulation of gonadotropin hormones (1) (2) (3) (4) . NK3R has been shown to be expressed in neurons within the GnRH neuron network, including kisspeptin neurons and GnRH neurons themselves (8, 10, 11) . The central administration of senktide was shown to induce c-fos, a marker of neuronal activation, in NK3R-expressing kisspeptin neurons (8) . The mechanism we have uncovered downstream of NK3R in GT1-7 cells that uses activation of PKC, SRF, and Elk-1 may be a general mechanism for c-fos gene induction in other NK3R-expressing neurons. In conclusion, we propose a model whereby NKB induces the transcription of the c-fos gene by a PKC-dependent mechanism involving the phosphorylation of Elk-1 and enhanced transcriptional activation by SRF through formation of a ternary complex at SRE and Ets sites in the c-fos promoter. This novel information regarding the mechanism of NK3R signaling to induce c-fos gene transcription may assist in the characterization of loss-of-function mutations observed in humans with idiopathic hypogonadotropic hypogonadism. Furthermore, our results reveal key pathways that regulate PKC signaling and the transcriptional activity of SRF and Elk-1 in GnRH neurons by NKB and its receptor that are important for puberty, infertility, and contraception.
